Compare Stocks: ABCL, RYTM, TGTX, and COGT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$9.49 +36.9%	$6.22	$2.74 ▼ $9.76	$2.91B	1.2	5.82 million shs	21.68 million shs
COGT Cogent Biosciences	$41.00 -3.3%	$37.39	$10.72 ▼ $43.73	$6.99B	0.38	2.23 million shs	514,335 shs
RYTM Rhythm Pharmaceuticals	$116.31 +0.6%	$102.51	$74.50 ▼ $122.20	$7.97B	1.92	791,079 shs	111,104 shs
TGTX TG Therapeutics	$49.50 -0.5%	$51.47	$25.28 ▼ $59.30	$7.56B	1.62	2.23 million shs	338,171 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+21.37%	+1.91%	+32.00%	+63.06%
COGT Cogent Biosciences	0.00%	+8.89%	+9.06%	+24.31%	+286.77%
RYTM Rhythm Pharmaceuticals	0.00%	+16.50%	+6.67%	+32.31%	+25.71%
TGTX TG Therapeutics	0.00%	-4.36%	-12.89%	+15.35%	+86.30%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$9.49 +36.9%	$6.22	$2.74 ▼ $9.76	$2.91B	1.2	5.82 million shs	21.68 million shs
COGT Cogent Biosciences	$41.00 -3.3%	$37.39	$10.72 ▼ $43.73	$6.99B	0.38	2.23 million shs	514,335 shs
RYTM Rhythm Pharmaceuticals	$116.31 +0.6%	$102.51	$74.50 ▼ $122.20	$7.97B	1.92	791,079 shs	111,104 shs
TGTX TG Therapeutics	$49.50 -0.5%	$51.47	$25.28 ▼ $59.30	$7.56B	1.62	2.23 million shs	338,171 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	0.00%	+21.37%	+1.91%	+32.00%	+63.06%
COGT Cogent Biosciences	0.00%	+8.89%	+9.06%	+24.31%	+286.77%
RYTM Rhythm Pharmaceuticals	0.00%	+16.50%	+6.67%	+32.31%	+25.71%
TGTX TG Therapeutics	0.00%	-4.36%	-12.89%	+15.35%	+86.30%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.67	Moderate Buy	$9.40	35.64% Upside
COGT Cogent Biosciences	2.85	Moderate Buy	$45.90	8.28% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$142.44	23.18% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	26.61% Upside

Current Analyst Ratings Breakdown

Latest ABCL, RYTM, TGTX, and COGT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/6/2026	ABCL AbCellera Biologics	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $9.00
8/6/2026	ABCL AbCellera Biologics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $12.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	RYTM Rhythm Pharmaceuticals	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$160.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$142.00 ➝ $143.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$141.00 ➝ $155.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$155.00 ➝ $160.00
8/4/2026	TGTX TG Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$78.00

(Data available from 8/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	28.28	N/A	N/A	$3.23 per share	2.15
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$3.84 per share	N/A
RYTM Rhythm Pharmaceuticals	$189.76M	41.76	N/A	N/A	$2.08 per share	55.59
TGTX TG Therapeutics	$616.29M	12.36	$2.80 per share	17.76	$4.08 per share	12.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	N/A
COGT Cogent Biosciences	-$328.94M	-$2.17	N/A	N/A	N/A	N/A	-104.27%	-54.64%	8/10/2026 (Estimated)
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	N/A
TGTX TG Therapeutics	$447.18M	$2.74	18.16	17.90	1.65	55.22%	73.49%	34.14%	N/A

Latest ABCL, RYTM, TGTX, and COGT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	COGT Cogent Biosciences	-$0.5550	N/A	N/A	N/A	$0.00 million	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million
5/11/2026	Q1 2026	ABCL AbCellera Biologics	-$0.22	-$0.14	+$0.08	-$0.14	$5.41 million	$8.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
COGT Cogent Biosciences	0.41	15.14	15.14
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
COGT Cogent Biosciences	N/A
RYTM Rhythm Pharmaceuticals	N/A
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
COGT Cogent Biosciences	6.59%
RYTM Rhythm Pharmaceuticals	5.90%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
COGT Cogent Biosciences	80	170.87 million	159.61 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

ABCL, RYTM, TGTX, and COGT Headlines

Recent News About These Companies

TG Therapeutics, Inc. $TGTX Position Trimmed by First Trust Advisors LP

August 10 at 3:28 AM | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Price Target Raised to $72.00

August 10 at 1:48 AM | americanbankingnews.com

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages

August 8 at 4:13 AM | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price

August 7 at 12:59 PM | marketbeat.com

Q4 EPS Estimates for TG Therapeutics Lifted by HC Wainwright

August 7 at 1:28 AM | americanbankingnews.com

California State Teachers Retirement System Increases Stock Position in TG Therapeutics, Inc. $TGTX

August 6, 2026 | marketbeat.com

Q3 EPS Estimates for TG Therapeutics Cut by HC Wainwright

August 6, 2026 | americanbankingnews.com

HC Wainwright Expects Higher Earnings for TG Therapeutics

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Purchased by Sei Investments Co.

August 5, 2026 | marketbeat.com

Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Stock Holdings Boosted by Dimensional Fund Advisors LP

August 5, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Stock Price Down 9% Following Weak Earnings

August 5, 2026 | americanbankingnews.com

TG Therapeutics Q3 EPS Estimate Lowered by HC Wainwright

August 4, 2026 | marketbeat.com

TG Therapeutics : TGTX

August 4, 2026 | 247wallst.com

TG Therapeutics (TGTX) Is Down 15.9% After Q2 Miss But Raised 2026 Outlook - What's Changed

August 4, 2026 | finance.yahoo.com

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

August 3, 2026 | seekingalpha.com

TG Therapeutics: Q2 Earnings Snapshot

August 3, 2026 | wtop.comW

TG Therapeutics (TGTX) Q2 2026 Earnings

August 3, 2026 | 247wallst.com

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

August 3, 2026 | uk.finance.yahoo.com

Three noteworthy biotechs just reported earnings — and only one recovered

August 3, 2026 | msn.com

TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss

August 3, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, RYTM, TGTX, and COGT Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$9.48 +2.55 (+36.84%)

As of 10:26 AM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Cogent Biosciences NASDAQ:COGT

$41.00 -1.39 (-3.28%)

As of 10:26 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Rhythm Pharmaceuticals NASDAQ:RYTM

$116.31 +0.68 (+0.59%)

As of 10:26 AM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$49.50 -0.26 (-0.52%)

As of 10:26 AM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCL, RYTM, TGTX, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCL, RYTM, TGTX, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCL, RYTM, TGTX, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, RYTM, TGTX, and COGT Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Cogent Biosciences NASDAQ:COGT

Rhythm Pharmaceuticals NASDAQ:RYTM

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCL, RYTM, TGTX, and COGT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCL, RYTM, TGTX, and COGT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCL, RYTM, TGTX, and COGT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, RYTM, TGTX, and COGT Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Cogent Biosciences NASDAQ:COGT

Rhythm Pharmaceuticals NASDAQ:RYTM

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools